Primo Biotechnology embodies disruptive innovation that advance clinical procedures for cancer management with molecular image-guided and targeted diagnosis and therapy. We are determined to lead in precision radiopharmaceutical approaches for the diagnosis and treatment of cancer.
Based in Taiwan, Primo is on a mission of promoting medical and radiopharma-tech integrated molecular imaging science for the world. We protect your health and happiness with scientific precision.
Innovation in RDC Therapeutics
Focused on the research and development of Radioligand Drug Conjugates (RDCs), we provide a comprehensive ecosystem—from isotope supply and targeted radiopharmaceutical development to automated synthesis and clinical support. Our mission is to lead the layout of innovative therapies and ensure precision medicine is truly accessible to all.
Drug Development & Manufacturin
Advancing RDC drug development through a multi-engine strategy, integrating precision and digital medicine to establish a cross-disciplinary innovation model.
Bridging Preclinical & Clinical Practice
With 10+ years of R&D expertise, we foster academic synergies to pioneer novel radiopharmaceuticals, bringing Taiwan’s nuclear medicine excellence to the global stage.
2025
Primo Fludeoxyglucose F 18 Injection Marketing in
PIC/S GMP Certification for Taoyuan Facility
2024
Exclusive Lu-177 Distribution for Taiwan
MOEA Potential Startup Award
2023
Construction Commencement of Taoyuan Facility
Taipei Highlight Enterprise Award
2022
SiTi Taipei R&D Grant Awarded
2021
Establishment of Primo
0
↑
Radiopharmaceutical R&D & Manufacturing
Manufacturing Process
Drug Patents & Publications
TFDA IND Approval Achieved
Clinical Research & Multi-Project Drug Manufacturing
Founder & Chairman
M.D.
Founder & CEO
Ph.D
CTO of Radiopharmaceutical Chemistry
Director of Research and Development
Application Manager
Marketing Manager
R&D Team Leader
Primo brings the highest quality radiopharmaceuticals and modern precision medical approaches for novel radioligand theranostics (RLT) to anyone in need.
Primo is also devoted to building a medical information platform, which records a patient’s whole body imaging using non-invasive methods. The platform optimizes customized medical needs and improves doctor-patient relationships, eventually developing an all-inclusive healthcare system for disease prevention.
Primo provides one-stop solutions encompassing drug development, manufacturing, regulatory affairs, and logistics support, while assisting healthcare professionals in optimized product applications.
CRO/CDMO
Full-cycle support from clinical trials to commercial manufacturing, ensuring premium quality and operational reliability.
Regulatory Affairs
Expert guidance through complex regulatory landscapes to accelerate marketing authorizations.
Radiopharmaceutical Delivering
High-efficiency logistics services ensuring timely delivery to healthcare facilities worldwide.
Primo provides a comprehensive portfolio of diagnostic and therapeutic radiopharmaceuticals to address unmet medical needs, with a strategic focus on advancing the development of Radioligand Theranostics (RLT).
Primo is dedicated to advancing cancer care through the innovation of Radioligand Therapy (RLT). We believe that RLT technology can unlock a broader therapeutic window, providing safer and more effective treatment options compared to existing standards of care.t RLT technology can unlock a broader therapeutic window, providing saer and more effective treatment options compared to existing standards of care.
